Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for
benign prostatic hypertrophy (BPH) as recommended by the American Urological Association
(AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the
morcellation portion of HoLEP to promote urine production in the post-operative setting and
to minimize the impact of fluid absorption during long periods of morcellation. The
intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated
with the dissemination of HoLEP across North America without evidence to support its routine
administration. With increasing surgical efficiency from improvements in laser and
morcellator technology, the role of intra-operative furosemide is unknown. This study is
designed to assess if there is a significant difference in same day discharge rates after
Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .